These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

539 related articles for article (PubMed ID: 27177423)

  • 1. Protocol: changes in rates of opioid overdose and poisoning events in an integrated health system following the introduction of a formulation of OxyContin® with abuse-deterrent properties.
    Janoff SL; Perrin NA; Coplan PM; Chilcoat HD; Campbell CI; Green CA
    BMC Pharmacol Toxicol; 2016 May; 17(1):21. PubMed ID: 27177423
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluating the potential impact of a reformulated version of oxycodone upon tampering, non-adherence and diversion of opioids: the National Opioid Medications Abuse Deterrence (NOMAD) study protocol.
    Degenhardt L; Larance B; Bruno R; Lintzeris N; Ali R; Farrell M
    Addiction; 2015 Feb; 110(2):226-37. PubMed ID: 25358480
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Changes in drug use patterns reported on the web after the introduction of ADF OxyContin: findings from the Researched Abuse, Diversion, and Addiction-Related Surveillance (RADARS) System Web Monitoring Program.
    Vosburg SK; Haynes C; Besharat A; Green JL
    Pharmacoepidemiol Drug Saf; 2017 Sep; 26(9):1044-1052. PubMed ID: 28653782
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Abuse-Deterrent Formulations and the Prescription Opioid Abuse Epidemic in the United States: Lessons Learned From OxyContin.
    Cicero TJ; Ellis MS
    JAMA Psychiatry; 2015 May; 72(5):424-30. PubMed ID: 25760692
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparing the effects of decreasing prescription opioid shipments and the release of an abuse deterrent OxyContin formulation on opioid overdose fatalities in WV: an interrupted time series study.
    Lundstrom EW; Dai Z; Groth CP; Hendricks B; Winstanley EL; Abate M; Smith GS
    Subst Abuse Treat Prev Policy; 2024 Jan; 19(1):4. PubMed ID: 38178238
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessing the accuracy of opioid overdose and poisoning codes in diagnostic information from electronic health records, claims data, and death records.
    Green CA; Perrin NA; Janoff SL; Campbell CI; Chilcoat HD; Coplan PM
    Pharmacoepidemiol Drug Saf; 2017 May; 26(5):509-517. PubMed ID: 28074520
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Understanding opioid overdose characteristics involving prescription and illicit opioids: A mixed methods analysis.
    Yarborough BJ; Stumbo SP; Janoff SL; Yarborough MT; McCarty D; Chilcoat HD; Coplan PM; Green CA
    Drug Alcohol Depend; 2016 Oct; 167():49-56. PubMed ID: 27520885
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sustained reduction of diversion and abuse after introduction of an abuse deterrent formulation of extended release oxycodone.
    Severtson SG; Ellis MS; Kurtz SP; Rosenblum A; Cicero TJ; Parrino MW; Gilbert MK; Buttram ME; Dasgupta N; BucherBartelson B; Green JL; Dart RC
    Drug Alcohol Depend; 2016 Nov; 168():219-229. PubMed ID: 27716575
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incidence of nonmedical use of OxyContin and other prescription opioid pain relievers before and after the introduction of OxyContin with abuse deterrent properties.
    Cheng HG; Coplan PM
    Postgrad Med; 2018 Aug; 130(6):568-574. PubMed ID: 29978755
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Opioids with abuse-deterrent properties: A regulatory and technological overview.
    Haddox JD
    J Opioid Manag; 2017; 13(6):397-413. PubMed ID: 29308587
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of abuse-deterrent OxyContin on prescription opioid utilization.
    Hwang CS; Chang HY; Alexander GC
    Pharmacoepidemiol Drug Saf; 2015 Feb; 24(2):197-204. PubMed ID: 25393216
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The introduction of a potentially abuse deterrent oxycodone formulation: Early findings from the Australian National Opioid Medications Abuse Deterrence (NOMAD) study.
    Degenhardt L; Bruno R; Ali R; Lintzeris N; Farrell M; Larance B
    Drug Alcohol Depend; 2015 Jun; 151():56-67. PubMed ID: 25910850
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rates of opioid dispensing and overdose after introduction of abuse-deterrent extended-release oxycodone and withdrawal of propoxyphene.
    Larochelle MR; Zhang F; Ross-Degnan D; Wharam JF
    JAMA Intern Med; 2015 Jun; 175(6):978-87. PubMed ID: 25895077
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Abuse of reformulated OxyContin: Updated findings from a sentinel surveillance sample of individuals assessed for substance use disorder.
    Cassidy TA; Thorley E; Black RA; DeVeaugh-Geiss A; Butler SF; Coplan P
    J Opioid Manag; 2017; 13(6):425-440. PubMed ID: 29308589
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of an abuse-deterrent opioid formulation (OxyContin) on opioid abuse-related outcomes in the postmarketing setting.
    Coplan PM; Chilcoat HD; Butler SF; Sellers EM; Kadakia A; Harikrishnan V; Haddox JD; Dart RC
    Clin Pharmacol Ther; 2016 Sep; 100(3):275-86. PubMed ID: 27170195
    [TBL] [Abstract][Full Text] [Related]  

  • 16. OxyContin abuse and overdose.
    Aquina CT; Marques-Baptista A; Bridgeman P; Merlin MA
    Postgrad Med; 2009 Mar; 121(2):163-7. PubMed ID: 19332974
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monitoring of internet forums to evaluate reactions to the introduction of reformulated OxyContin to deter abuse.
    McNaughton EC; Coplan PM; Black RA; Weber SE; Chilcoat HD; Butler SF
    J Med Internet Res; 2014 May; 16(5):e119. PubMed ID: 24800858
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of prescription opioids with abuse-deterrent technology to address opioid abuse.
    Michna E; Kirson NY; Shei A; Birnbaum HG; Ben-Joseph R
    Curr Med Res Opin; 2014 Aug; 30(8):1589-98. PubMed ID: 24738694
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trends in abuse of Oxycontin and other opioid analgesics in the United States: 2002-2004.
    Cicero TJ; Inciardi JA; Muñoz A
    J Pain; 2005 Oct; 6(10):662-72. PubMed ID: 16202959
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparing the Effect of Tampering on the Oral Pharmacokinetic Profiles of Two Extended-Release Oxycodone Formulations with Abuse-Deterrent Properties.
    Gudin J; Levy-Cooperman N; Kopecky EA; Fleming AB
    Pain Med; 2015 Nov; 16(11):2142-51. PubMed ID: 26108255
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.